Maintaining Our Plasma FVEs Following Encouraging Grifols Alzheimer's Data for Plasma Exchange
Grifols presented phase 2b/3 AMBAR data at Clinical Trials on Alzheimer's Disease (CTAD) in Barcelona on Oct. 27 that indicated a positive effect of plasma exchange on disease progression in patients with Alzheimer's, with a particularly strong effect in the subgroup of patients with moderate disease. While the analysis is not complete and several questions are still outstanding, we expect this to drive a limited amount of off-label demand for albumin (and potentially immunoglobulin) from plasma...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.